Neurology® Podcast IGLON5 Frequency in Idiopathic REM Sleep Behavior Disorder
Dec 19, 2024
Dr. Ron Postuma, a Neurologist at the Montreal Neurological Institute specializing in sleep and movement disorders, discusses the intriguing links between IGLON5 antibodies and idiopathic REM Sleep Behavior Disorder. He elaborates on how these findings could revolutionize diagnosis and treatment for such conditions. The conversation dives into the connection between REM behavior disorder and neurodegenerative diseases like Parkinson's, as well as the intricate challenges faced in identifying and managing IGLON5-related symptoms.
AI Snips
Chapters
Transcript
Episode notes
IGLON5 Frequency
- 1% of an unselected RBD patient cohort tested positive for IGLON5 antibodies.
- This was part of a broader study on synucleinopathy within the North American Prodromal Synucleinopathy Consortium.
RBD and Synucleinopathy Risk
- Patients with idiopathic REM behavior disorder (RBD) have a high risk of developing synucleinopathies like Parkinson's disease.
- The study cohort consisted of RBD patients without diagnosed synucleinopathies, confirmed by polysomnography.
IGLON5 Syndrome
- IGLON5 antibody syndrome is a newly recognized condition affecting the sleep-wake system.
- Symptoms include sleepwalking, insomnia, and RBD, often progressing rapidly with additional movement issues.